JP2024099041A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2024099041A5 JP2024099041A5 JP2024073463A JP2024073463A JP2024099041A5 JP 2024099041 A5 JP2024099041 A5 JP 2024099041A5 JP 2024073463 A JP2024073463 A JP 2024073463A JP 2024073463 A JP2024073463 A JP 2024073463A JP 2024099041 A5 JP2024099041 A5 JP 2024099041A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- atom
- acceptable salt
- compound according
- pharmacologically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025203466A JP2026026166A (ja) | 2018-09-06 | 2025-11-26 | 新規環状ジヌクレオチド誘導体及びその抗体薬物コンジュゲート |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2018167369 | 2018-09-06 | ||
| JP2018167369 | 2018-09-06 | ||
| PCT/JP2019/035198 WO2020050406A1 (ja) | 2018-09-06 | 2019-09-06 | 新規環状ジヌクレオチド誘導体及びその抗体薬物コンジュゲート |
| JP2020541321A JP7254818B2 (ja) | 2018-09-06 | 2019-09-06 | 新規環状ジヌクレオチド誘導体及びその抗体薬物コンジュゲート |
| JP2023050936A JP7483975B2 (ja) | 2018-09-06 | 2023-03-28 | 新規環状ジヌクレオチド誘導体及びその抗体薬物コンジュゲート |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023050936A Division JP7483975B2 (ja) | 2018-09-06 | 2023-03-28 | 新規環状ジヌクレオチド誘導体及びその抗体薬物コンジュゲート |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025203466A Division JP2026026166A (ja) | 2018-09-06 | 2025-11-26 | 新規環状ジヌクレオチド誘導体及びその抗体薬物コンジュゲート |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024099041A JP2024099041A (ja) | 2024-07-24 |
| JP2024099041A5 true JP2024099041A5 (https=) | 2025-01-14 |
Family
ID=69722459
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020541321A Active JP7254818B2 (ja) | 2018-09-06 | 2019-09-06 | 新規環状ジヌクレオチド誘導体及びその抗体薬物コンジュゲート |
| JP2023050936A Active JP7483975B2 (ja) | 2018-09-06 | 2023-03-28 | 新規環状ジヌクレオチド誘導体及びその抗体薬物コンジュゲート |
| JP2024073463A Ceased JP2024099041A (ja) | 2018-09-06 | 2024-04-30 | 新規環状ジヌクレオチド誘導体及びその抗体薬物コンジュゲート |
| JP2025203466A Pending JP2026026166A (ja) | 2018-09-06 | 2025-11-26 | 新規環状ジヌクレオチド誘導体及びその抗体薬物コンジュゲート |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020541321A Active JP7254818B2 (ja) | 2018-09-06 | 2019-09-06 | 新規環状ジヌクレオチド誘導体及びその抗体薬物コンジュゲート |
| JP2023050936A Active JP7483975B2 (ja) | 2018-09-06 | 2023-03-28 | 新規環状ジヌクレオチド誘導体及びその抗体薬物コンジュゲート |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025203466A Pending JP2026026166A (ja) | 2018-09-06 | 2025-11-26 | 新規環状ジヌクレオチド誘導体及びその抗体薬物コンジュゲート |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US12370263B2 (https=) |
| EP (2) | EP4524154A3 (https=) |
| JP (4) | JP7254818B2 (https=) |
| KR (4) | KR102567590B1 (https=) |
| CN (3) | CN118846110A (https=) |
| AU (2) | AU2019337051B2 (https=) |
| BR (1) | BR112021003472A2 (https=) |
| CA (1) | CA3251690A1 (https=) |
| CO (1) | CO2021004032A2 (https=) |
| DK (1) | DK3848054T3 (https=) |
| ES (1) | ES3017008T3 (https=) |
| FI (1) | FI3848054T3 (https=) |
| HR (1) | HRP20250345T1 (https=) |
| HU (1) | HUE071437T2 (https=) |
| IL (2) | IL315138A (https=) |
| LT (1) | LT3848054T (https=) |
| MX (1) | MX2021002107A (https=) |
| PH (1) | PH12021550442A1 (https=) |
| PL (1) | PL3848054T3 (https=) |
| PT (1) | PT3848054T (https=) |
| RS (1) | RS66662B1 (https=) |
| SG (1) | SG11202101526YA (https=) |
| SI (1) | SI3848054T1 (https=) |
| SM (1) | SMT202500141T1 (https=) |
| TW (3) | TWI825170B (https=) |
| WO (1) | WO2020050406A1 (https=) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102567590B1 (ko) | 2018-09-06 | 2023-08-17 | 다이이찌 산쿄 가부시키가이샤 | 신규 고리형 디뉴클레오티드 유도체 및 그 항체 약물 콘쥬게이트 |
| CA3168368A1 (en) * | 2020-03-06 | 2021-09-10 | Masayuki Ishizaki | Antibody-drug conjugate including novel cyclic dinucleotide derivative |
| WO2021206158A1 (ja) | 2020-04-10 | 2021-10-14 | 小野薬品工業株式会社 | がん治療方法 |
| TW202227479A (zh) | 2020-09-02 | 2022-07-16 | 日商第一三共股份有限公司 | 新穎內－β－Ｎ－乙醯葡萄糖胺苷酶 |
| CN116867795A (zh) * | 2021-02-01 | 2023-10-10 | 第一三共株式会社 | 抗体－免疫刺激剂偶联物的新型制造方法 |
| TW202241454A (zh) | 2021-02-01 | 2022-11-01 | 日商第一三共股份有限公司 | 抗體－免疫賦活化劑共軛物之新穎製造方法 |
| CA3212691A1 (en) | 2021-03-12 | 2022-09-15 | Daiichi Sankyo Company, Limited | Glycan, and method for producing medicine containing glycan |
| EP4326314A4 (en) * | 2021-04-23 | 2025-12-17 | Univ Maryland | FC-GLYCAN REMODELING FOR SITE-SPECIFIC ANTIBODIES CONJUGATION AND APPLICATIONS THEREOF |
| US11806405B1 (en) | 2021-07-19 | 2023-11-07 | Zeno Management, Inc. | Immunoconjugates and methods |
| TW202320858A (zh) | 2021-07-19 | 2023-06-01 | 美商薩諾管理公司 | 免疫接合物及方法 |
| CN115703845A (zh) * | 2021-08-05 | 2023-02-17 | 中国科学院上海药物研究所 | 寡糖连接子与侧链亲水性片段组合的糖链定点抗体-药物偶联物，其制法及用途 |
| WO2023061405A1 (zh) * | 2021-10-12 | 2023-04-20 | 成都科岭源医药技术有限公司 | 一种高稳定性的靶向接头-药物偶联物 |
| US20250346622A1 (en) | 2021-10-29 | 2025-11-13 | Daiichi Sankyo Company, Limited | Novel oligosaccharide, manufacturing intermediate for novel oligosaccharide, and method for manufacturing these |
| IL312728A (en) | 2021-11-30 | 2024-07-01 | Daiichi Sankyo Co Ltd | Protease-cleavable masked antibodies |
| US20250170255A1 (en) | 2022-02-09 | 2025-05-29 | Daiichi Sankyo Company, Limited | Environmentally-responsive masked antibody and use thereof |
| US20250207169A1 (en) | 2022-03-02 | 2025-06-26 | Daiichi Sankyo Company, Limited | METHOD FOR PRODUCING Fc-CONTAINING MOLECULE |
| JP2025166269A (ja) * | 2022-07-29 | 2025-11-06 | 第一三共株式会社 | 抗腫瘍効果を有する抗体薬物複合体の新規製造方法 |
| AU2023336004A1 (en) | 2022-08-29 | 2025-03-06 | Daiichi Sankyo Company, Limited | Antibody-drug conjugate including mutant fc region |
| WO2024053574A1 (ja) | 2022-09-09 | 2024-03-14 | 第一三共株式会社 | 新規なオリゴ糖、該オリゴ糖の製造中間体、及びそれらの製造方法 |
| WO2024107827A1 (en) * | 2022-11-16 | 2024-05-23 | The Broad Institute, Inc. | Therapeutic exploitation of sting channel activity |
| CN120659785A (zh) | 2022-11-30 | 2025-09-16 | 里珍纳龙药品有限公司 | Tlr7激动剂及其抗体-药物缀合物 |
| WO2025005240A1 (ja) | 2023-06-30 | 2025-01-02 | 第一三共株式会社 | 活性炭材料を使用する精製工程を含む抗体－薬物コンジュゲートの製造方法 |
| TW202545568A (zh) * | 2024-01-29 | 2025-12-01 | 日商第一三共股份有限公司 | 抗her2抗體-藥物結合物與其他劑之組合 |
| TW202543682A (zh) * | 2024-02-28 | 2025-11-16 | 日商第一三共股份有限公司 | 抗ｃｄｈ６抗體—藥物結合物與其他劑之組合 |
Family Cites Families (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1988007089A1 (en) | 1987-03-18 | 1988-09-22 | Medical Research Council | Altered antibodies |
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| US5885573A (en) | 1993-06-01 | 1999-03-23 | Arch Development Corporation | Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies |
| AU691811B2 (en) | 1993-06-16 | 1998-05-28 | Celltech Therapeutics Limited | Antibodies |
| CN100506277C (zh) | 2001-11-01 | 2009-07-01 | Uab研究基金会 | 肿瘤坏死因子相关细胞凋亡诱导配体受体的选择性抗体和其它治疗剂的联合体系 |
| IL149820A0 (en) | 2002-05-23 | 2002-11-10 | Curetech Ltd | Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency |
| ES2392525T3 (es) | 2002-07-15 | 2012-12-11 | F. Hoffmann-La Roche Ag | Tratamiento del cáncer con el anticuerpo dirigido contra ErbB2 rhuMAb 2C4 |
| AU2004213053C1 (en) | 2003-02-20 | 2009-07-16 | Seagen Inc. | Anti-CD70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders |
| CA2647632C (en) | 2006-03-27 | 2017-06-27 | University Of Maryland Biotechnology Institute | Glycoprotein synthesis and remodeling by enzymatic transglycosylation |
| HRP20170407T1 (hr) | 2007-08-30 | 2017-05-05 | Daiichi Sankyo Company, Limited | Anti-epha2 anitijelo |
| US8809496B2 (en) | 2009-09-03 | 2014-08-19 | The Noguchi Institute | Production method of 11-sugar sialylglycopeptide |
| US9175326B2 (en) | 2011-03-03 | 2015-11-03 | University Of Maryland, Baltimore | Transglycosylation activity of glycosynthase mutants of an endo-beta-N-acetylglucosaminidase (endo-D) from streptococcus pneumoniae |
| US10851174B2 (en) | 2011-03-03 | 2020-12-01 | University Of Maryland, Baltimore | Core fucosylated glycopeptides and glycoproteins: chemoenzymatic synthesis and uses thereof |
| CA2862925C (en) | 2012-02-10 | 2020-01-21 | University Of Maryland, Baltimore | Chemoenzymatic glycoengineering of antibodies and fc fragments thereof |
| DK2907824T3 (en) | 2012-10-11 | 2018-07-23 | Daiichi Sankyo Co Ltd | ANTIBODY-drug conjugate |
| PL2931738T3 (pl) | 2012-12-13 | 2019-07-31 | Aduro Biotech, Inc. | Kompozycje zawierające cykliczne dinukleotydy purynowe o zdefiniowanej stereochemii i sposoby ich otrzymywania i zastosowania |
| PT2934598T (pt) | 2012-12-19 | 2018-07-24 | Univ Texas | Focalização farmacêutica de uma trajetória de sinalização de dinucleótido cíclico de mamífero |
| WO2014179335A1 (en) | 2013-04-29 | 2014-11-06 | Memorial Sloan Kettering Cancer Center | Compositions and methods for altering second messenger signaling |
| EP2996472B1 (en) | 2013-05-18 | 2019-03-27 | Aduro Biotech, Inc. | Compositions and methods for inhibiting "stimulator of interferon gene" dependent signalling |
| RS59500B1 (sr) | 2013-05-18 | 2019-12-31 | Aduro Biotech Inc | Sastavi i metode za aktiviranje signaliziranja koje je zavisno od „stimulatora gena za interferon“ |
| US9549944B2 (en) | 2013-05-18 | 2017-01-24 | Aduro Biotech, Inc. | Compositions and methods for inhibiting “stimulator of interferon gene”—dependent signalling |
| EP2935608A1 (en) | 2013-10-14 | 2015-10-28 | SynAffix B.V. | Modified glycoprotein, protein-conjugate and process for the preparation thereof |
| WO2015057066A1 (en) | 2013-10-14 | 2015-04-23 | Synaffix B.V. | Glycoengineered antibody, antibody-conjugate and methods for their preparation |
| EP3057618B1 (en) | 2013-10-14 | 2022-12-14 | SynAffix B.V. | Glycoengineered antibody, antibody-conjugate and methods for their preparation |
| EP3058083B1 (en) | 2013-10-14 | 2018-04-11 | SynAffix B.V. | Modified glycoprotein, protein-conjugate and process for the preparation thereof |
| US10092644B2 (en) | 2013-11-22 | 2018-10-09 | Brock University | Use of fluorinated cyclic dinucleotides as oral vaccine adjuvants |
| PE20170198A1 (es) | 2014-06-04 | 2017-04-08 | Glaxosmithkline Ip Dev Ltd | Dinucleotidos ciclicos como moduladores de sting |
| DE102014214408A1 (de) | 2014-07-23 | 2016-01-28 | Wacker Chemie Ag | Härtbare Organopolysiloxanzusammensetzungen |
| ES2763235T3 (es) | 2014-12-15 | 2020-05-27 | Henkel Ag & Co Kgaa | Composición detergente que comprende variantes de subtilasa |
| US11559581B2 (en) | 2015-01-09 | 2023-01-24 | Oxford University Innovation Limited | Antibody conjugates and methods of making the antibody conjugates |
| HK1248603A1 (zh) | 2015-03-10 | 2018-10-19 | Aduro Biotech, Inc. | 用於活化"干扰素基因的刺激剂"依懒性信号传导的组合物和方法 |
| US20180117171A1 (en) | 2015-04-01 | 2018-05-03 | President And Fellows Of Harvard College | Immunoconjugates for programming or reprogramming of cells |
| EP4180455A1 (en) | 2015-06-29 | 2023-05-17 | Daiichi Sankyo Company, Limited | Method for selectively manufacturing antibody-drug conjugate |
| EP3323886B1 (en) | 2015-07-16 | 2020-10-21 | Daiichi Sankyo Company, Limited | Endos mutant enzyme |
| WO2017025491A1 (en) | 2015-08-12 | 2017-02-16 | F. Hoffmann-La Roche Ag | Bace1 inhibitors |
| CR20180101A (es) | 2015-08-13 | 2018-04-12 | Merck Sharp & Dohme | Compuestos di-nucleóticos cíclicos como agonistas de sting |
| US11453697B1 (en) | 2015-08-13 | 2022-09-27 | Merck Sharp & Dohme Llc | Cyclic di-nucleotide compounds as sting agonists |
| CA3002236A1 (en) * | 2015-10-28 | 2017-05-04 | Aduro Biotech, Inc. | Compositions and methods for activating "stimulator of interferon gene"-dependent signalling |
| TN2018000112A1 (en) | 2015-10-29 | 2019-10-04 | Novartis Ag | Antibody conjugates comprising toll-like receptor agonist |
| TWI704154B (zh) | 2015-12-03 | 2020-09-11 | 英商葛蘭素史克智慧財產發展有限公司 | 新穎化合物 |
| EP3386536A4 (en) | 2015-12-07 | 2019-07-31 | Opi Vi- IP Holdco LLC | COMPOSITION OF ANTIBODY CONSTRUCT AGONIST CONJUGATES AND METHOD FOR USE THEREOF |
| US20170158772A1 (en) | 2015-12-07 | 2017-06-08 | Opi Vi - Ip Holdco Llc | Compositions of antibody construct - agonist conjugates and methods of use thereof |
| WO2017123657A1 (en) | 2016-01-11 | 2017-07-20 | Gary Glick | Cyclic dinucleotides for treating conditions associated with sting activity such as cancer |
| RS67188B1 (sr) | 2016-01-11 | 2025-10-31 | Innate Tumor Immunity Inc | Ciklični dinukleotidi za lečenje stanja povezanih sa aktivnošću sting kao što je kancer |
| SG10201912074PA (en) | 2016-03-18 | 2020-02-27 | Immune Sensor Llc | Cyclic di-nucleotide compounds and methods of use |
| JP2019510802A (ja) | 2016-04-07 | 2019-04-18 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ | タンパク質調節物質として有用な複素環アミド |
| US11486223B2 (en) | 2016-04-07 | 2022-11-01 | Chevron U.S.A. Inc. | Method for sealing a void in a well using smart gels |
| AU2017246802B2 (en) | 2016-04-07 | 2021-04-01 | Chevron U.S.A. Inc. | Smart gel sealants for well systems |
| HRP20220936T1 (hr) | 2016-04-07 | 2022-10-28 | Glaxosmithkline Intellectual Property Development Limited | Heterociklički amidi korisni kao modulatori proteina |
| EP4159749A3 (en) | 2016-07-01 | 2023-06-14 | Daiichi Sankyo Company, Limited | A method for producing fc-containing molecule with remodeled sugar chain |
| WO2018009466A1 (en) | 2016-07-05 | 2018-01-11 | Aduro Biotech, Inc. | Locked nucleic acid cyclic dinucleotide compounds and uses thereof |
| US11033569B2 (en) | 2016-07-06 | 2021-06-15 | Sperovie Biosciences, Inc. | Compounds,Compositions, and methods for the treatment of disease |
| US20190345191A1 (en) | 2016-08-31 | 2019-11-14 | Innate Tumor Immunity, Inc. | Cyclic dinucleotide analogs for treating conditions associated with sting (stimulator of interferon genes) activity |
| US10537590B2 (en) | 2016-09-30 | 2020-01-21 | Boehringer Ingelheim International Gmbh | Cyclic dinucleotide compounds |
| US10414747B2 (en) | 2016-10-04 | 2019-09-17 | Merck Sharp & Dohme Corp. | Benzo[b]thiophene compounds as sting agonists |
| EP3523314A1 (de) | 2016-10-07 | 2019-08-14 | Biolog Life Science Institute Forschungslabor Und Biochemica-Vertrieb GmbH | Benzimidazolhaltige cyclische dinukleotide, verfahren zu deren herstellung und ihre verwendung zur aktivierung von stimulator von interferongenen (sting)-abhängigen signalwegen |
| SG10201912173RA (en) | 2016-10-07 | 2020-02-27 | Daiichi Sankyo Co Ltd | Therapy for drug-resistant cancer by administration of anti-her2 antibody/drug conjugate |
| WO2018100558A2 (en) | 2016-12-01 | 2018-06-07 | Takeda Pharmaceutical Company Limited | Cyclic dinucleotide |
| JP2018090562A (ja) * | 2016-12-01 | 2018-06-14 | 武田薬品工業株式会社 | 環状ジヌクレオチド |
| WO2018118665A1 (en) * | 2016-12-20 | 2018-06-28 | Merck Sharp & Dohme Corp. | Cyclic dinucleotide sting agonists for cancer treatment |
| WO2018140831A2 (en) * | 2017-01-27 | 2018-08-02 | Silverback Therapeutics, Inc. | Tumor targeting conjugates and methods of use thereof |
| TW202532102A (zh) | 2017-05-15 | 2025-08-16 | 日商第一三共股份有限公司 | 抗體－藥物結合物及其用途 |
| JP6967739B2 (ja) | 2017-11-14 | 2021-11-17 | パナソニックＩｐマネジメント株式会社 | 給湯機 |
| KR102567590B1 (ko) | 2018-09-06 | 2023-08-17 | 다이이찌 산쿄 가부시키가이샤 | 신규 고리형 디뉴클레오티드 유도체 및 그 항체 약물 콘쥬게이트 |
-
2019
- 2019-09-06 KR KR1020217009642A patent/KR102567590B1/ko active Active
- 2019-09-06 IL IL315138A patent/IL315138A/en unknown
- 2019-09-06 CA CA3251690A patent/CA3251690A1/en active Pending
- 2019-09-06 LT LTEPPCT/JP2019/035198T patent/LT3848054T/lt unknown
- 2019-09-06 CN CN202410810871.3A patent/CN118846110A/zh active Pending
- 2019-09-06 SM SM20250141T patent/SMT202500141T1/it unknown
- 2019-09-06 CN CN202410810879.XA patent/CN118878620A/zh active Pending
- 2019-09-06 US US17/273,666 patent/US12370263B2/en active Active
- 2019-09-06 SG SG11202101526YA patent/SG11202101526YA/en unknown
- 2019-09-06 HR HRP20250345TT patent/HRP20250345T1/hr unknown
- 2019-09-06 RS RS20250327A patent/RS66662B1/sr unknown
- 2019-09-06 PT PT198574337T patent/PT3848054T/pt unknown
- 2019-09-06 HU HUE19857433A patent/HUE071437T2/hu unknown
- 2019-09-06 EP EP25154566.1A patent/EP4524154A3/en active Pending
- 2019-09-06 BR BR112021003472-2A patent/BR112021003472A2/pt unknown
- 2019-09-06 SI SI201930902T patent/SI3848054T1/sl unknown
- 2019-09-06 AU AU2019337051A patent/AU2019337051B2/en active Active
- 2019-09-06 ES ES19857433T patent/ES3017008T3/es active Active
- 2019-09-06 KR KR1020237027378A patent/KR102810513B1/ko active Active
- 2019-09-06 EP EP19857433.7A patent/EP3848054B1/en active Active
- 2019-09-06 TW TW108132368A patent/TWI825170B/zh active
- 2019-09-06 IL IL281247A patent/IL281247B2/en unknown
- 2019-09-06 CN CN201980058151.3A patent/CN112714649B/zh active Active
- 2019-09-06 TW TW112114344A patent/TWI861820B/zh active
- 2019-09-06 TW TW113138233A patent/TWI905974B/zh active
- 2019-09-06 JP JP2020541321A patent/JP7254818B2/ja active Active
- 2019-09-06 DK DK19857433.7T patent/DK3848054T3/da active
- 2019-09-06 PL PL19857433.7T patent/PL3848054T3/pl unknown
- 2019-09-06 WO PCT/JP2019/035198 patent/WO2020050406A1/ja not_active Ceased
- 2019-09-06 KR KR1020237005621A patent/KR102567591B1/ko active Active
- 2019-09-06 FI FIEP19857433.7T patent/FI3848054T3/fi active
- 2019-09-06 KR KR1020257016237A patent/KR20250078590A/ko active Pending
- 2019-09-06 MX MX2021002107A patent/MX2021002107A/es unknown
-
2021
- 2021-03-02 PH PH12021550442A patent/PH12021550442A1/en unknown
- 2021-03-30 CO CONC2021/0004032A patent/CO2021004032A2/es unknown
-
2023
- 2023-02-27 AU AU2023201159A patent/AU2023201159B2/en active Active
- 2023-03-28 JP JP2023050936A patent/JP7483975B2/ja active Active
-
2024
- 2024-04-22 US US18/642,667 patent/US20240293567A1/en active Pending
- 2024-04-30 JP JP2024073463A patent/JP2024099041A/ja not_active Ceased
-
2025
- 2025-11-26 JP JP2025203466A patent/JP2026026166A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024099041A5 (https=) | ||
| JP2023105175A (ja) | グルクロニド薬物－リンカーの調製のためのプロセスおよびその中間体 | |
| US20080293800A1 (en) | Cytotoxic Compounds and Conjugates | |
| WO2017165851A1 (en) | Process for the preparation of pegylated drug-linkers and intermediates thereof | |
| CN103570792B (zh) | 蟾毒灵衍生物、其制备方法、药物组合物及用途 | |
| US20060247295A1 (en) | Cytotoxic compounds and conjugates with cleavable substrates | |
| JP2021523225A5 (https=) | ||
| US20060004081A1 (en) | Cytotoxic compounds and conjugates | |
| WO2018148650A1 (en) | Trigger-activatable sugar conjugates for cancer-selective labeling and targeting | |
| KR20080068084A (ko) | 씨씨-1065 유사체를 제조하기 위한 방법 및 화합물 | |
| JP2006511534A5 (https=) | ||
| TR201802539T4 (tr) | CC-1065 analoglarının ve bifonksiyonel bağlayıcıların konjugatları. | |
| JPWO2020028608A5 (https=) | ||
| PL195014B1 (pl) | Nowe, podstawione pochodne kwasu N-benzyloindol-3-iloglioksylowego o działaniu przeciwnowotworowym oraz ich zastosowanie | |
| KR20260051045A (ko) | 이관능성 링커 화합물, 항체 약물 접합체 및 이의 제조 방법과 용도 | |
| JPWO2019213445A5 (https=) | ||
| JP2026507549A (ja) | 改良された特性を有するテトラジン類 | |
| US20130005696A1 (en) | Bufadienolide derivatives, preparing process thereof, composition comprising the same and the use thereof | |
| JP5612467B2 (ja) | Ｆｍｏｃをベースとした加水分解性リンカーの調製方法 | |
| CN111417408A (zh) | 药物接头化合物的制备方法 | |
| KR20180055135A (ko) | 벤조사이아졸 유도체가 결합된 리간드-금속 복합체 및 이의 제조 방법 | |
| JP2002533418A (ja) | アントラキノン抗癌剤 | |
| US20250161506A1 (en) | Antibody Drug Conjugate Based on Metal N-Heterocyclic Carbene Complex, a Method of Preparing the Same and the Use of the Same in Anticancer Treatment | |
| JP4590198B2 (ja) | 葉酸誘導体の製造方法 | |
| KR20170041562A (ko) | 벤조셀레노펜계 화합물 및 이를 포함하는 항체-약물 결합체 |